MedTrace Logo

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

NCT05212779 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2024-02-01

No results posted yet for this study

Summary

Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DIAGNOSTIC_TEST

Signatera testing

26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.

DIAGNOSTIC_TEST

Altera Testing

6ml blood and tissue sample.

Sponsors & Collaborators

  • Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

    lead OTHER

Principal Investigators

  • John Nakayama, MD · Allegheny Health Network

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-07
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212779 on ClinicalTrials.gov